|
1
|
Green DM, D’Angio GJ, Beckwith JB, Breslow
NE, Grundy PE, Ritchey ML and Thomas PR: Wilms tumor. CA Cancer J
Clin. 461:46–63. 1996. View Article : Google Scholar
|
|
2
|
Li W, Kessler P, Yeger H, Alami J, Reeve
AE, Heathcott R, Skeen J and Williams BR: A gene expression
signature for relapse of primary wilms tumors. Cancer Res.
65:2592–2601. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grundy PE, Telzerow PE, Breslow N,
Moksness J, Huff V and Paterson MC: Loss of heterozygosity for
chromosomes 16q and 1p in wilms’ tumors predicts an adverse
outcome. Cancer Res. 54:2331–2333. 1994.
|
|
4
|
Grundy PE, Breslow NE, Li S, Perlman E,
Beckwith JB, Ritchey ML, Shamberger RC, et al: Loss of
heterozygosity for chromosomes 1p and 16q is an adverse prognostic
factor in favorable-histology wilms tumor: a report from the
national wilms tumor study group. J Clin Oncol. 23:7312–7321. 2005.
View Article : Google Scholar
|
|
5
|
Messahel B, Williams R, Ridolfi A, A’hern
R, Warren W, Tinworth L, Hobson R, et al: Allele loss at 16q
defines poorer prognosis wilms tumour irrespective of treatment
approach in the UKW1–3 clinical trials: a children’s cancer and
leukaemia group (CCLG) study. Eur J Cancer. 45:819–826.
2009.PubMed/NCBI
|
|
6
|
Bednarek AK, Laflin KJ, Daniel RL, Liao Q,
Hawkins KA and Aldaz CM: WWOX, a novel WW domain-containing protein
mapping to human chromosome 16q23.3–24.1, a region frequently
affected in breast cancer. Cancer Res. 60:2140–2145.
2000.PubMed/NCBI
|
|
7
|
Aqeilan RI, Donati V, Palamarchuk A,
Trapasso F, Kaou M, Pekarsky Y, Sudol M and Croce CM: WW
domain-containing proteins, WWOX and YAP, compete for interaction
with ErbB-4 and modulate its transcriptional function. Cancer Res.
65:6764–6772. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Aqeilan RI, Donati V, Gaudio E, Nicoloso
MS, Sundvall M, Korhonen A, Lundin J, et al: Association of Wwox
with ErbB4 in breast cancer. Cancer Res. 67:9330–9336. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Aqeilan RI, Pekarsky Y, Herrero JJ,
Palamarchuk A, Letofsky J, Druck T, Trapasso F, et al: Functional
association between Wwox tumor suppressor protein and P73, a P53
homolog. Proc Natl Acad Sci USA. 101:4401–4406. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aqeilan RI, Palamarchuk A, Weigel RJ,
Herrero JJ, Pekarsky Y and Croce CM: Physical and functional
interactions between the Wwox tumor suppressor protein and the
AP-2gamma transcription factor. Cancer Res. 64:8256–8261. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guler G, Huebner K, Himmetoglu C, Jimenez
RE, Costinean S, Volinia S, Pilarski RT, et al: Fragile histidine
triadprotein, WW domain-containing oxidoreductase protein Wwox, and
activator protein 2gamma expression levels correlate with basal
phenotype in breast cancer. Cancer. 115:899–908. 2009. View Article : Google Scholar
|
|
12
|
Gaudio E, Palamarchuk A, Palumbo T,
Trapasso F, Pekarsky Y, Croce CM and Aqeilan RI: Physical
association with WWOX suppresses C-Jun transcriptional activity.
Cancer Res. 66:11585–11589. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Aqeilan RI, Hassan MQ, de Bruin A, Hagan
JP, Volinia S, Palumbo T, Hussain S, et al: The WWOX tumor
suppressor is essential for postnatal survival and normal bone
metabolism. J Biol Chem. 283:21629–21639. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Aqeilan RI, Trapasso F, Hussain S,
Costinean S, Marshall D, Pekarsky Y, Hagan JP, et al: Targeted
deletion of Wwox reveals a tumor suppressor function. Proc Natl
Acad Sci USA. 104:3949–3954. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maeda N, Semba S, Nakayama S, Yanagihara K
and Yokozaki H: Loss of WW domain-containing oxidoreductase
expression in the progression and development of gastric carcinoma:
clinical and histopathologic correlations. Virchows Arch.
457:423–432. 2010. View Article : Google Scholar
|
|
16
|
Aqeilan RI, Kuroki T, Pekarsky Y, Albagha
O, Trapass F, Baffa R, Huebner K, et al: Loss of WWOX expression in
gastric carcinoma. Clin Cancer Res. 10:3053–3058. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kuroki T, Trapasso F, Shiraishi T, Alder
H, Mimori K, Mori M and Croce CM: Genetic alterations of the tumor
suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer
Res. 62:2258–2260. 2002.PubMed/NCBI
|
|
18
|
Kuroki T, Yendamuri S, Trapasso F,
Matsuyama A, Aqeilan RI, Alder H, Rattan S, et al: The tumor
suppressor gene WWOX at FRA16D is involved in pancreatic
carcinogenesis. Clin Cancer Res. 10:2459–2465. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yendamuri S, Kuroki T, Trapasso F, Henry
AC, Dumon KR, Huebner K, Williams NN, et al: WW domain containing
oxidoreductase gene expression is altered in non-small cell lung
cancer. Cancer Res. 63:878–881. 2003.PubMed/NCBI
|
|
20
|
Chen T, Sahin A and Aldaz CM: Deletion map
of chromosome 16q inductalcarcinoma in situ of the breast: refining
a putative tumor suppressor gene region. Cancer Res. 56:5605–5609.
1996.PubMed/NCBI
|
|
21
|
Iliopoulos D, Guler G, Han SY, Johnston D,
Druck T, McCorkell KA, Palazzo J, et al: Fragile genes as
biomarkers: epigenetic control of WWOX and FHIT in lung, breast and
bladder cancer. Oncogene. 24:1625–1633. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ishii H, Vecchione A, Furukawa Y,
Sutheesophon K, Han SY, Druck T, Kuroki T, et al: Expression of
FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol
Cancer Res. 1:940–947. 2003.PubMed/NCBI
|
|
23
|
Vujanic GM, Sandstedt B, Harms D, Kelsey
A, Leuschner I and de Kraker J: Revised international society of
paediatric oncology (SIOP) working classification of renal tumors
of childhood. Med Pediatr Oncol. 38:79–82. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Holemon H, Korshunova Y, Ordway JM, Bedell
JA, Citek RW, Lakey N, Leon J, et al: MethylScreen: DNA methylation
density monitoringusing quantitative PCR. Biotechniques.
43:683–693. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Skotnicka-Klonowicz G, Rieske P,
Bartkowiak J, Szymik-Kantorowicz S, Daszkiewicz P and
Debiec-Rychter M: 16q heterozygosity loss in Wilms’ tumour in
children and its clinical importance. Eur J Surg Oncol. 26:61–66.
2000.
|
|
26
|
Feinberg AP: Imprinting of a genomic
domain of 11p15 and loss of imprinting in cancer: an introduction.
Cancer Res. 59:S1743–S1746. 1999.PubMed/NCBI
|
|
27
|
Loeb DM, Korz D, Katsnelson M, Burwell EA,
Friedman AD and Sukumar S: Cyclin E is a target of WT1
transcriptional repression. J Biol Chem. 277:19627–19632. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Berrebi D, Leclerc J, Schleiermacher G,
Zaccaria I, Boccon-Gibod L, Fabre M, Jaubert F, et al: High cyclin
E staining index in blastemal, stromal or epithelial cells is
correlated with tumor aggressiveness in patients with
nephroblastoma. PLoS One. 3:e22162008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Faussillon M, Monnier L, Junien C and
Jeanpierre C: Frequent overexpression of cyclin D2/cyclin-dependent
kinase 4 in Wilms’ tumor. Cancer Lett. 221:67–75. 2005.PubMed/NCBI
|
|
30
|
Scharnhorst V, Dekker P, van der Eb AJ and
Jochemsen AG: Physical interaction between wilms tumor 1 and P73
proteins modulates their functions. J Biol Chem. 275:10202–10211.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ghanem MA, van der Kwast TH, Den Hollander
JC, Sudaryo MK, van den Heuvel MM, Noordzij MA, Nijman RJ, et al:
The prognostic significance of apoptosis-associated proteins BCL-2,
BAX and BCL-X in clinical nephroblastoma. Br J Cancer.
85:1557–1563. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tanaka K, Granata C, Wang Y, O’Briain DS
and Puri P: Apoptosis and Bcl-2 oncogene expression in wilms’
tumor. Pediatr Surg Int. 15:243–247. 1999.
|
|
33
|
Wetli SC, Leuschner I, Harms D, Rufle A,
Foerster A, Bihl M, Graf N, et al: KIT, PDGFRalpha and EGFR
analysis in nephroblastoma. Virchows Arch. 452:637–650. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vasei M, Modjtahedi H, Ale-Booyeh O,
Mosallaei A, Kajbafzadeh AM, Shahriari M, Ghaderi AA, et al:
Amplification and expression of EGFR and ERBB2 in Wilms’ tumor.
Cancer Genet Cytogenet. 194:88–95. 2009.
|
